Clinical trial · no report yet · Phase 2
EXCALIBUR
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
- NCT04915508 ↗
- Active, not recruiting
- Jonsson Comprehensive Cancer Center
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 59 | |
| Podcasts | 25 | |
| X threads | 17 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy (EXCALIBUR)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Adenocarcinoma; Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Hormone Therapy; Stereotactic Body Radiation Therapy
- Arms
- Treatment (SBRT, hormone therapy) · Experimental
- Enrollment
- 165
- Primary outcomes
- Change of Expanded Prostate Cancer Index (EPIC) score for the gastrointestinal domain
- Change of Expanded Prostate Cancer Index (EPIC) score for the genitourinary domain
- Sponsor
- Jonsson Comprehensive Cancer Center
- Start
- Jun 23, 2021
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04915508 · updated Jul 17, 2026